Denosumab for Giant Cell Tumour of Bone

BoneNeoadjuvant

Denosumab for Giant Cell Tumour of Bone

Giant cell tumour of bone

Overview

  • Denosumab is a fully human monoclonal antibody targeting RANKL (receptor activator of nuclear factor kappa-B ligand)
  • RANKL is expressed by the neoplastic stromal cells of GCT and drives osteoclast-mediated bone destruction
  • Denosumab blocks RANKL, inhibiting osteoclast recruitment, resulting in tumour consolidation and new bone formation
  • Approved indications: unresectable GCT; pre-operative downstaging to allow limb salvage; recurrent/metastatic GCT; skeletally immature patients
  • Brand name: Xgeva (120 mg subcutaneous)

Regimen & Dosing

Regimen

  • Denosumab 120 mg subcutaneous injection
  • Loading doses: Day 1, Day 8, Day 15 of Cycle 1
  • Maintenance: 120 mg SC every 4 weeks (28-day cycles)
  • Duration: until disease progression, unacceptable toxicity, or surgical resection
  • Pre-operative use: typically 3–6 months prior to planned surgery

Dosing

  • Denosumab 120 mg SC on Days 1, 8, and 15 of Cycle 1 (loading phase)
  • Denosumab 120 mg SC on Day 1 of each subsequent 28-day cycle (maintenance)
  • No dose reduction schedule - consider dose delay for toxicity
  • Calcium and vitamin D supplementation mandatory: calcium ≥500 mg/day + vitamin D ≥400 IU/day unless hypercalcaemia present

Eligibility & Contraindications

Eligibility

  • Histologically confirmed giant cell tumour of bone
  • Unresectable disease (spine, pelvis, sacrum, skull base)
  • Resectable disease where denosumab may reduce surgical morbidity (downstaging)
  • Recurrent or metastatic GCT
  • Skeletally immature patients where surgery would damage physis
  • No prior severe hypersensitivity to denosumab

Contraindications

  • Hypocalcaemia - correct before initiating (risk of severe symptomatic hypocalcaemia)
  • Pregnancy and breastfeeding (teratogenic - effective contraception required)
  • Severe renal impairment (eGFR <30 mL/min) - increased risk of hypocalcaemia; use with caution
  • Active dental/jaw infection or planned invasive dental procedure - risk of osteonecrosis of the jaw (ONJ)
  • Prior history of ONJ

Monitoring

  • Baseline: serum calcium, phosphate, magnesium, creatinine, FBC, dental review
  • Calcium and vitamin D supplementation throughout treatment
  • Serum calcium at each cycle (Day 1): withhold if symptomatic hypocalcaemia
  • Dental review before initiation; avoid invasive dental procedures during treatment
  • Bone turnover markers (ALP, CTX) - optional, may reflect response
  • MRI of primary site every 3–6 months to assess response
  • Monitor for osteonecrosis of the jaw (ONJ): jaw pain, swelling, exposed bone
  • Rebound hypercalcaemia after cessation - monitor calcium for 8–10 weeks after stopping
  • FDG-PET or bone scan at clinician's discretion for disease assessment

Notes

  • Denosumab does NOT cure GCT - surgery remains the definitive treatment in most resectable cases
  • Rebound phenomenon after cessation: rapid tumour re-growth and hypercalcaemia reported - plan surgery before discontinuation
  • Pathological changes induced by denosumab (ossification) can make histological grading difficult - inform pathologist
  • Pulmonary 'metastases' (benign implants) in GCT may respond to denosumab - monitor with CT chest
  • Malignant GCT: denosumab has limited activity - treat as high-grade sarcoma
  • ONJ risk: ~1–2%; dental hygiene and avoidance of invasive procedures reduces risk
  • Do not abruptly discontinue without surgical plan - rebound tumour activity well documented
  • Off-label use for aneurysmal bone cyst showing emerging evidence

Medical disclaimer

The content on Sarcopedia is for educational and informational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical diagnosis or treatment. Always consult with a qualified physician regarding any health concerns or before starting any new treatment. Reliance on any information provided on this site is solely at your own risk.